Stockscreener 앱 받기
7.87
0.06%
0.02
전일 마감가:
$7.85
열려 있는:
$7.74
하루 거래량:
134.48K
Relative Volume:
0.38
시가총액:
$174.05M
수익:
$155.00K
순이익/손실:
$-30.01M
주가수익비율:
-4.7126
EPS:
-1.67
순현금흐름:
$-11.98M
1주 성능:
-8.56%
1개월 성능:
-2.06%
6개월 성능:
+15.01%
1년 성능:
-33.54%
1일 변동 폭
$7.30
$8.135
1주일 범위
$7.30
$8.69
52주 변동 폭
$4.32
$13.30
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
INMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
7.85 | 174.05M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.65 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.27 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
617.93 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.32 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.11 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-21 | 개시 | Alliance Global Partners | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-22 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-01 | 개시 | Robert W. Baird | Outperform |
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St
INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat
Raymond James raises INmune Bio stock target to $23 - MSN
(INMB) Investment Report - Stock Traders Daily
INmune Bio price target raised to $23 from $22 at Scotiabank - Yahoo Finance
Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times
INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq
Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks
INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria
Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
INmune Bio's CORDStrom shows promise in RDEB treatment - MSN
Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex
Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa
BLA Submission Planned for CORDStrom in RDEB - MD Magazine
Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com
Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider
INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa
INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat
INmune Bio Inc (INMB) shows promising results - US Post News
Trading Day Review: INmune Bio Inc (INMB) Loses Momentum, Closing at 9.31 - The Dwinnex
Analyzing INmune Bio Inc (INMB) After Recent Trading Activity - Knox Daily
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
(INMB) Proactive Strategies - Stock Traders Daily
INmune Bio (NASDAQ:INMB) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inmune Bio Inc 주식 (INMB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
1.77%
0.65%
자본화:
|
볼륨(24시간):